Teva Pharmaceutical Industries (TEVA) Intangibles (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Intangibles for 18 consecutive years, with $3.4 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Intangibles fell 16.78% year-over-year to $3.4 billion; the trailing twelve-month figure through Jun 2026 stood at $3.4 billion (down 16.78% YoY), and the FY2025 full-year result was $3.8 billion, down 14.42% from the prior year.
• Intangibles eased to $3.4 billion in Q2 2026 per TEVA's latest filing, from $3.6 billion in the prior quarter.
• Across five years, Intangibles topped out at $7.1 billion in Q1 2022 and bottomed at $3.4 billion in Q2 2026.
• Historically, Intangibles has averaged $5.1 billion across 5 years, with a median of $5.0 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Intangibles decreased 18.37% in 2022, then decreased 13.58% in 2023.
• Over 5 years, Intangibles stood at $6.3 billion in 2022, then decreased by 14.08% to $5.4 billion in 2023, then retreated by 17.99% to $4.4 billion in 2024, then retreated by 14.42% to $3.8 billion in 2025, then slipped by 8.83% to $3.4 billion in 2026.
• According to Business Quant data, Intangibles over the past three periods registered $3.4 billion, $3.6 billion, and $3.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.